Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis

Recruiting now · Not applicable

Conditions studied: Hypertriglyceridemia Induced Acute Pancreatitis

In brief

The severity of hypertriglyceridemia induced acute pancreatitis (HTG-AP) is closely related to the serum triglyceride (TG) levels. The higher the TG levels, the greater the risk of developing severe acute pancreatitis (SAP). Previous expert consensus has pointed out that the key to treating HTG-AP is to rapidly lower serum TG levels to below 5.65 mmol/L. Evolocumab is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, which is often used to treat familial hypercholesterolemia, mixed dyslipidemia and atherosclerotic cardiovascular disease. At the same time, evolocumab also has the effect of reducing TG and may provide a feasible option for the management of HTG-AP. However, its efficacy and safety in reducing TG in patients with HTG-AP remain controversial. This study is a multicenter randomized controlled trial to evaluate the efficacy and safety of adding evolocumab to conventional lipid-lowering therapy in patients with HTG-AP.

Key facts

Study ID

NCT07388420

Run by

General Hospital of Shenyang Military Region

People needed

40

Starts

2026-01-02

Expected to finish

2026-12-31

Last updated by the study team

2026-02-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18\~75 years
• Patients with HTG-AP
• Mixed hyperlipidemia
• Sign the informed consent form

You may not qualify if…

• Patients who have received lipid-lowering drugs or blood purification treatment
• Patients who have used evolocumab within one month before admission
• Patients who are accompanied by diseases that can seriously affect the survival
• Patients who have participated in the clinical research of other drugs within one month
• Patients who are pregnant or breastfeeding
• Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies
• Other circumstances that researchers consider not suitable for participation in this study

Where it is running

• Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area) — Shenyang, Liaoning, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.